AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 133 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Follow-Up Questions
AC Immune SA의 CEO는 누구입니까?
Prof. Dr. Andrea Pfeifer은 2003부터 회사에 합류한 AC Immune SA의 Chief Executive Officer입니다.
ACIU 주식의 가격 성능은 어떻습니까?
ACIU의 현재 가격은 $3.1이며, 전 거래일에 increased 6.93% 하였습니다.
AC Immune SA의 주요 사업 주제나 업종은 무엇입니까?
AC Immune SA은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
AC Immune SA의 시가총액은 얼마입니까?
AC Immune SA의 현재 시가총액은 $311.3M입니다
AC Immune SA는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 6명의 분석가가 AC Immune SA에 대한 분석 평가를 실시했으며, 이는 4명의 강력한 매수, 4명의 매수, 1명의 보유, 0명의 매도, 그리고 4명의 강력한 매도를 포함합니다
